DavidHGutmannMDPhD

Donald O. Schnuck Family Professor, Neurology, Washington University School of Medicine; Director, Washington University Neurofibromatosis Center

Join to view full profile

Dr. Gutmann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gutmann's full profile

Already have an account?

Office
1 Childrens Pl
# Div
Saint Louis, MO 63110
Phone+1 314-362-1408

Fax+1 314-454-2523

Summary

David H. Gutmann received his undergraduate, graduate (PhD) and medical (MD) degrees from the University of Michigan. Following his residency training in Neurology at the University of Pennsylvania, he returned to the University of Michigan for research fellowship training with Dr. Francis Collins. During that time, he identified the neurofibromatosis type 1 (NF1) protein and began to elucidate its function as a negative RAS regulator. In late 1993, Dr. Gutmann was recruited to Washington University, becoming a full professor in 2001 and the Donald O. Schnuck Family Professor in 2002. He established the St. Louis Children’s Hospital Neurofibromatosis Clinical Program in 1994 and the Washington University Neurofibromatosis Center in 2004.

For the past 30 years, his laboratory has focused on understanding the genomic, molecular and cellular basis for nervous system problems affecting children and adults with NF1 using both human induced pluripotent stem cells and novel genetically engineered mouse strains. Dr. Gutmann has published over 500 peer-reviewed manuscripts, and his research laboratory has been continuous funded by the NIH since 1993, including a NINDS R35 Research Program Award.

Gutmann has been recognized for his achievements with numerous awards, including the 2012 Children’s Tumor Foundation Frederich von Recklinghausen Lifetime Achievement Award, a 2017 Alexander von Humboldt Award, the 2019 Society for Neuro-Oncology Abhijit Guha Award, the 2020 American Academy of Neurology Neuro-Oncology Scientific Award, and the 2020 American Association of Neurology triennial George W. Jacoby Award. He is an elected Fellow of the American Academy of Neurology, the American Neurological Association, the Association of American Physicians, the American Association for the Advancement of Science, and the National Academy of Medicine, as well as a former member of the National Institute of Neurological Disorders and Stroke Advisory Council.

Education & Training

University of Pennsylvania Health SystemResidency, Neurology, 1987 - 1990
University of Pennsylvania Health SystemInternship, Internal Medicine, 1986 - 1987
University of Michigan Medical SchoolClass of 1986

Certifications & Licensure

IL State Medical License 2020 - 2026
MO State Medical License 1993 - 2026
MI State Medical License 1990 - 2012
PA State Medical License 1987 - 2006
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Elected Fellow Association of American Physicians, 2022
Elected Member National Academy of Medicine, 2022
Elected Fellow American Association for the Advancement of Science, 2020
Neuro-Oncology Scientific Award American Academy of Neurology, 2020
Triennial George W. Jacoby Award American Neurological Association, 2020
Elected Fellow American Academy of Neurology, 2018
Distinguished Faculty Research Award Washington University, 2013
Frederich Von Recklinghausen Award Children's Tumor Foundation, 2012
Elected Member The American Society for Clinical Investigation, 2003
Elected Member American Neurological Association, 1997
Join now to see all

Clinical Trials

A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 Start of enrollment: 2009 Jul 01
Completed
Phase 2
Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas Start of enrollment: 2010 Jul 10
Completed
Phase 2
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Start of enrollment: 2013 May 15
Completed
Phase 2
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Start of enrollment: 2014 Jun 01
Completed
Phase 2
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Start of enrollment: 2014 Jun 01
Completed
Phase 2
Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma Start of enrollment: 2013 Apr 16
Terminated
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Human single cell RNA-sequencing reveals a targetable CD8exhausted T cell population that maintains mouse low-grade glioma growth.
Rasha Barakat, Jit Chatterjee, Rui Mu, Xuanhe Qi, Xingxing Gu
Nature Communications. 2024-11-28
SRF-deficient astrocytes provide neuroprotection in mouse models of excitotoxicity and neurodegeneration.
Surya Chandra Rao Thumu, Monika Jain, Sumitha Soman, Soumen Das, Vijaya Verma
Elife. 2024-02-09
21 citations
Pediatric low-grade glioma: State-of-the-art and ongoing challenges.
Jason Fangusaro, David T Jones, Roger J Packer, David H Gutmann, Till Milde
Neuro-Oncology. 2024-01-05

Press Mentions

Jazz, Genetics, and Neurofibromatosis September 9th, 2023
Epilepsy drug stops nervous system tumor growth in miceMay 19th, 2022
Asthma may reduce risk of brain tumors — but how?December 23rd, 2021
Join now to see all

Grant Support

T cell regulation of low-grade gliomaNational Cancer Institute2022–2027
Neuronal regulation of low-grade gliomagenesisNational Cancer Institute2022–2027
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease HeterogeneityNational Institutes of Health2016–2024
Neurofibromin Regulation Of Neural Stem Cell Function In Vitro And In VivoNational Institute Of Neurological Disorders And Stroke2010–2012
Stromal Contributions To NF1 Glioma Formation And GrowthNational Cancer Institute2009–2012
Targeting Stoma-Tumor Co-Dependency For Glioma TherapyNational Cancer Institute2009–2011
Regulation And Role Of Mtor In Neurofibromin Growth ControlNational Cancer Institute2008–2011
Integrative Approaches To Stroma-Directed Glioma TherapyNational Institute Of Neurological Disorders And Stroke2010
Molecular Determinants Of Neural Stem Cell FunctionNational Institute Of Neurological Disorders And Stroke2007–2008
Identification And Preclinical Evaluation Of New Brain Tumor TherapiesNational Institute Of Neurological Disorders And Stroke2006–2007
Preclinical Models For Human AstrocytomasNational Institute Of Neurological Disorders And Stroke2001–2004
Neurofibromatosis Foundation International ConsortiumNational Institute Of Neurological Disorders And Stroke2003
Protein 4.1 Tumor Suppressors In Meningioma PathogenesisNational Institute Of Neurological Disorders And Stroke2001–2003
Functional Analysis Of NF2 Gene MutationsNational Institute Of Neurological Disorders And Stroke1997–2003
Neurofibromin As A Negative Regulator For AstrocytesNational Institute Of Neurological Disorders And Stroke1999–2002
Regulation Of NF1 Gene Expression During DifferentiationNational Institute Of Neurological Disorders And Stroke1995–1999
Characteriza. Of Neurofibromatosis Type 1 Gene ProductNational Institute Of Neurological Disorders And Stroke1995–1996
Neurofibromatosis 1 Gene ProductNational Institute Of Neurological Disorders And Stroke1994
Characterization Of The Neurofibromatosis 1 Gene ProductNational Institute Of Neurological Disorders And Stroke1993
Characterization Of The Neurofibromatosis 1 Gene ProductNational Institute Of Neurological Disorders And Stroke1992–1993